Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

10. Juni 2014 aktualisiert von: Boehringer Ingelheim

Pramipexole Special Survey on Long-Term Use

The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

1645

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Japan
      • Agano, Japan
        • Boehringer Ingelheim Investigational Site
      • Aizuwakamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Akashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Akita, Japan
        • Boehringer Ingelheim Investigational Site
      • Asahikawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Asakura, Japan
        • Boehringer Ingelheim Investigational Site
      • Ayagawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Azumino, Japan
        • Boehringer Ingelheim Investigational Site
      • Bando, Japan
        • Boehringer Ingelheim Investigational Site
      • Beppu, Japan
        • Boehringer Ingelheim Investigational Site
      • Bihoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Chiba, Japan
        • Boehringer Ingelheim Investigational Site
      • Chikusei, Japan
        • Boehringer Ingelheim Investigational Site
      • Chuo, Japan
        • Boehringer Ingelheim Investigational Site
      • Date, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebina, Japan
        • Boehringer Ingelheim Investigational Site
      • Eiheiji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuchu, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujieda, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujisawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujiyoshida, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukui, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Geisei, Japan
        • Boehringer Ingelheim Investigational Site
      • Gifu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ginowan, Japan
        • Boehringer Ingelheim Investigational Site
      • Hachinohe, Japan
        • Boehringer Ingelheim Investigational Site
      • Hadano, Japan
        • Boehringer Ingelheim Investigational Site
      • Haebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Hagahama, Japan
        • Boehringer Ingelheim Investigational Site
      • Hakodate, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamada, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Hayashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashimurayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiosaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiyamato, Japan
        • Boehringer Ingelheim Investigational Site
      • Himeji, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiratsuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirosaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiroshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Hita, Japan
        • Boehringer Ingelheim Investigational Site
      • Hofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ibaragi, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichikikushikino, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iizuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikeda, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikoma, Japan
        • Boehringer Ingelheim Investigational Site
      • Ina, Japan
        • Boehringer Ingelheim Investigational Site
      • Inazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Inba, Japan
        • Boehringer Ingelheim Investigational Site
      • Inuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Isezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Itoigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwata, Japan
        • Boehringer Ingelheim Investigational Site
      • Joetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kahoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Kajiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakegawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamisu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kanazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kannonji, Japan
        • Boehringer Ingelheim Investigational Site
      • Karatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kasukabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kato, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawagoe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawatana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kikugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kirishima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kitakyushu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyose, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyotake, Japan
        • Boehringer Ingelheim Investigational Site
      • Kizugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kochi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kodaira, Japan
        • Boehringer Ingelheim Investigational Site
      • Kofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Koga, Japan
        • Boehringer Ingelheim Investigational Site
      • Kokubunji, Japan
        • Boehringer Ingelheim Investigational Site
      • Komae, Japan
        • Boehringer Ingelheim Investigational Site
      • Komatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Komoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Koriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurashiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurayoshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kure, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurume, Japan
        • Boehringer Ingelheim Investigational Site
      • Kushiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Kutchan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kuwana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyonan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Maibara, Japan
        • Boehringer Ingelheim Investigational Site
      • Maizuru, Japan
        • Boehringer Ingelheim Investigational Site
      • Marugame, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuda, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsudo, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsue, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsumoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Mibu, Japan
        • Boehringer Ingelheim Investigational Site
      • Mihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Miki, Japan
        • Boehringer Ingelheim Investigational Site
      • Minakami, Japan
        • Boehringer Ingelheim Investigational Site
      • Minamata, Japan
        • Boehringer Ingelheim Investigational Site
      • Minobu, Japan
        • Boehringer Ingelheim Investigational Site
      • Misashino, Japan
        • Boehringer Ingelheim Investigational Site
      • Mito, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyakonojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Mooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Morioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriya, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Muroran, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagakute, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaokakyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nangoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Nara, Japan
        • Boehringer Ingelheim Investigational Site
      • Narita, Japan
        • Boehringer Ingelheim Investigational Site
      • Naruto, Japan
        • Boehringer Ingelheim Investigational Site
      • Nichinan, Japan
        • Boehringer Ingelheim Investigational Site
      • Niigata, Japan
        • Boehringer Ingelheim Investigational Site
      • Niihama, Japan
        • Boehringer Ingelheim Investigational Site
      • Nikko, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishigo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishio, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishitokyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nobeoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Noboribetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Numazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Obama, Japan
        • Boehringer Ingelheim Investigational Site
      • Obihiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Odate, Japan
        • Boehringer Ingelheim Investigational Site
      • Odawara, Japan
        • Boehringer Ingelheim Investigational Site
      • Ofunato, Japan
        • Boehringer Ingelheim Investigational Site
      • Ogaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Ohzu, Japan
        • Boehringer Ingelheim Investigational Site
      • Oiso, Japan
        • Boehringer Ingelheim Investigational Site
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site
      • Ojiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Okawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Okayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Omaezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Omura, Japan
        • Boehringer Ingelheim Investigational Site
      • Omuta, Japan
        • Boehringer Ingelheim Investigational Site
      • Onga, Japan
        • Boehringer Ingelheim Investigational Site
      • Onojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Onomichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Otsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ozu, Japan
        • Boehringer Ingelheim Investigational Site
      • Sado, Japan
        • Boehringer Ingelheim Investigational Site
      • Saga, Japan
        • Boehringer Ingelheim Investigational Site
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Saitama, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakai, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakaide, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakata, Japan
        • Boehringer Ingelheim Investigational Site
      • Saku, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanjo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sano, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanyoonoda, Japan
        • Boehringer Ingelheim Investigational Site
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sasebo, Japan
        • Boehringer Ingelheim Investigational Site
      • Seijo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sendai, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimabara, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimonoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimotsuke, Japan
        • Boehringer Ingelheim Investigational Site
      • Shingu, Japan
        • Boehringer Ingelheim Investigational Site
      • Shinshiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Shizuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Shunan, Japan
        • Boehringer Ingelheim Investigational Site
      • Soo, Japan
        • Boehringer Ingelheim Investigational Site
      • Suita, Japan
        • Boehringer Ingelheim Investigational Site
      • Tajimi, Japan
        • Boehringer Ingelheim Investigational Site
      • Takamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Takanabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Takaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasago, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takatsuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takehara, Japan
        • Boehringer Ingelheim Investigational Site
      • Toda, Japan
        • Boehringer Ingelheim Investigational Site
      • Togitsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokoname, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Adachi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Bunkyo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Chiyoda-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Edogawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Itabashi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Katsushika-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Kita-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Meguro-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Minayo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nakano-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nerima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Ota-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Setagaya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinagawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinjuku-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Suginami-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Toshima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomakomai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomiai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tondabayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Toon, Japan
        • Boehringer Ingelheim Investigational Site
      • Toride, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyoake, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyonaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsubata, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuchiura, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsukuba, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuruoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Uchinada, Japan
        • Boehringer Ingelheim Investigational Site
      • Ueda, Japan
        • Boehringer Ingelheim Investigational Site
      • Uji, Japan
        • Boehringer Ingelheim Investigational Site
      • Ujo, Japan
        • Boehringer Ingelheim Investigational Site
      • Urayasu, Japan
        • Boehringer Ingelheim Investigational Site
      • Uruma, Japan
        • Boehringer Ingelheim Investigational Site
      • Utsunomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Wakayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamagata, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamaguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Yanai, Japan
        • Boehringer Ingelheim Investigational Site
      • Yao, Japan
        • Boehringer Ingelheim Investigational Site
      • Yashiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokkaichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokote, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoshinogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Yufu, Japan
        • Boehringer Ingelheim Investigational Site
      • Zama, Japan
        • Boehringer Ingelheim Investigational Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Parkinson's disease patients in daily clinical settings

Beschreibung

Inclusion Criteria:

Patients with Parkinson's disease

Exclusion Criteria:

Patients should have been treated according to the Japanese insert slip

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events
Zeitfenster: during 18 months
The aim of this Post Marketing Surveillance (PMS) was to obtain long-term safety data with treatment of pramipexole in Parkinson's disease (PD) patients. Therefore these items were considered as a safety evaluation.
during 18 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical Global Impression of Improvement
Zeitfenster: 18 months
Investigators evaluation of the PD symptoms on a rating scale of 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
18 months
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Zeitfenster: Baseline and at 18 months (or at the time of discontinuation)
Motor examination is assessed by 27 questionnaire items in UPDRS Part III section. Each item is scored from 0 (best) to 4 (worst), and the total score of UPDRS Part III is from 0 (best) to 108 (worst). A decrease in the score means improvement.
Baseline and at 18 months (or at the time of discontinuation)
Change From Baseline in Modified Hoehn & Yahr Rating Scale
Zeitfenster: Baseline and at 18 months (or at the time of discontinuation)
A severity of PD symptom are assessed by Modified Hoehn & Yahr rating scale. This scale consist of 10 levels including additional evaluation levels defined in Japan. Ten levels are described by 0 (best), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 (worst).
Baseline and at 18 months (or at the time of discontinuation)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Boehringer Ingelheim

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Februar 2004

Primärer Abschluss (Tatsächlich)

1. März 2009

Studienanmeldedaten

Zuerst eingereicht

31. Januar 2008

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Februar 2008

Zuerst gepostet (Schätzen)

14. Februar 2008

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

11. Juli 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. Juni 2014

Zuletzt verifiziert

1. Juni 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 248.547

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Parkinson Krankheit

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Uzbekistan

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren